Hanna Squire

Hanna Squire


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
LCLaura Ciaccio
Laura Ciaccio
HFHolly Fountain
Holly Fountain
EBElizabeth Beech
Elizabeth Beech
CBColin S. Brown
Colin S. Brown
ADAlicia Demirjian
Alicia Demirjian
SBSabine Bou-Antoun
Sabine Bou-Antoun
Objectives Inappropriate prescribing of antibiotics is a key driver of antimicrobial resistance. This study aimed to describe urine sampling rates and antibiotic prescribing for patients with lower urinary tract infections (UTIs) in English general practice. Design A retrospective population-based study using administrative data. Setting IQVIA Medical Research Database (IMRD) data from general practices in England, 2015–2022. Participants Patients who have consulted with an uncomplicated UTI in England general practices captured in the IMRD. Outcome measures Trends in UTI episodes (episodes were defined as UTI diagnosis codes occurring within 14 days of each other), testing and antibiotic prescribing on the same day as initial UTI consultation were assessed from January 2015 to December 2022. Associations, using univariate and multivariate logistic regressions, were examined between consultation and demographic factors on the odds of a urine test. Results There were 743 350 UTI episodes; 50.8% had a urine test. Testing rates fluctuated with an upward trend and large decline in 2020. Same-day UTI antibiotic prescribing occurred in 78.2% of episodes. In multivariate modelling, factors found to decrease odds of a urine test included age ≥85 years (0.83, 95% CI 0.82 to 0.84), consultation type (remote vs face to face, 0.45, 95% CI 0.45 to 0.46), episodes in London compared with the South (0.74, 95% CI 0.72 to 0.75) and increasing practice size (0.77, 95% CI 0.76 to 0.78). Odds of urine tests increased in males (OR 1.11, 95% CI 1.10 to 1.13), for those episodes without a same-day UTI antibiotic (1.10, 95% CI 1.04 to 1.16) for episodes for those with higher deprivation status (Indices of Multiple Deprivation 8 vs 1, 1.51, 95% CI 1.48 to 1.54). Compared with 2015, 2016–2019 saw increased odds of testing while 2020 and 2021 saw decreases, with 2022 showing increased odds. Conclusion Urine testing for UTI in general practice in England showed an upward trend, with same-day antibiotic prescribing remaining consistent, suggesting greater alignment to national guidelines. The COVID-19 pandemic impacted testing rates, though as of 2022, they began to recover.

16 January 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
OCOlivia D. Conroy
Olivia D. Conroy
AMAndrea Mazzella
Andrea Mazzella
HCHannah Choi
Hannah Choi
JEJocelyn Elmes
Jocelyn Elmes
MWMatt Wilson
Matt Wilson
RHRussell Hope
Russell Hope
Background: Patients in critical care units (CCUs) are at an increased risk of bloodstream infections (BSIs), which can be associated with central vascular catheters (CVCs). This study describes BSIs, CVC-BSIs, organism distribution, percentage of antimicrobial resistant (AMR) organisms, and case fatality rates (CFRs) over the first six years of a voluntary national CCU surveillance programme in England. Methods: Surveillance data on BSIs, CVCs, and bed-days between 04/2017 and 03/2023 for adult CCUs were linked to mortality and AMR data, and crude rates were calculated. Results: The rates of CCU-BSIs and CCU-CVC-BSIs were stable for the first three years (3.6 and 1.7 per 1000 bed-days in 2019/20), before increasing by 75% and 94% in 2020/21, respectively, and returning to near pre-pandemic levels by 2022/23. Gram-negative bacteria accounted for 50.3% of all CCU-BSIs, followed by Gram-positive bacteria (39.6%) and Candida spp. (8.6%). Klebsiella spp. saw increases in percentage AMR, whereas other organisms saw declines or similar levels. The overall CFR was 30.2%. Conclusions: BSI incidence in CCUs remained stable across the study period, except for an increase in 2020/21 which reverted by 2022/23. These data provide a benchmark for CCUs and give insight into long-term AMR patterns where comparable national data are limited.

24 March 2023 in Medical Sciences Forum
Verified
Conference Paper
Open access
PDF file
RGRebecca Guy
Rebecca Guy
HHHannah Higgins
Hannah Higgins
JRJamie Rudman
Jamie Rudman
HFHolly Fountain
Holly Fountain
KBKirsty Bennet
Kirsty Bennet
KHKatherine L Henderson
Katherine L Henderson
The English surveillance programme for antimicrobial utilisation and resistance (ESPAUR) antimicrobial resistance (AMR) chapter reports on bacterial, viral, and fungal AMR trends between 2017 and 2021 in England. A 10.8% increase in patient episodes of bacteraemia or fungaemia was observed, and the estimated burden of resistance decreased by 4.2%. Individuals with an antimicrobial-resistant strain (resistant to ≥1 key AMR burden-defined antibiotics) had a higher crude case fatality rate (18.1%) compared to those with a susceptible strain (16.3%). The effect of deprivation on carbapenemase-producing organisms (CPO) incidence, and the impact of the AMR burden across ethnic groups, have been described for the first time. Understanding the impact of ethnicity, deprivation, regional divergence, and potential confounders remains a crucial avenue of enquiry to target appropriate AMR interventions. These findings were presented at the ESPAUR Report webinar on 23 November 2022.

1 March 2023 in Medical Sciences Forum
Verified
Conference Paper
Open access
PDF file
ALAlessandra Lochen
Alessandra Lochen
HSHanna Squire
Hanna Squire
Diane Ashiru-OredopeDiane Ashiru-Oredope
Diane Ashiru-Oredope
KHKieran S Hand
Kieran S Hand
HHHassan Hartman
Hassan Hartman
HSHanna Squire
Hanna Squire
The UK Health Security Agency’s (UKHSA) COVID-19 therapeutics programme was commissioned by the Department of Health and Social Care with the remit to evaluate the use and role of COVID-19 treatments. COVID-19 therapeutics data were assessed from two main data sources: novel therapy requests via Blueteq and medicines supply data via Rx-info. The five COVID-19 therapies in use in England between 1 October 2021 and 31 March 2022 included nirmatrelvir plus ritonavir, remdesivir, molnupiravir, sotrovimab, and casirivimab with imdevimab. During this time period, treatment requests for novel therapies against COVID-19 were submitted for nearly 52,000 patients in England. The UKHSAs COVID-19 therapeutics programme has been key to supporting the deployment of novel COVID-19 therapies in England by undertaking genomic, virological, and epidemiologic surveillance, through both national surveillance systems and academic collaboration. Effective therapies are particularly important for protecting the health of patients at greater risk of developing severe COVID-19. This national surveillance and stewardship programme was successfully rolled out at pace at the start of the pandemic and leads on work nationally to reduce the development of resistance. These findings were presented at the ESPAUR Report webinar on 23 November 2022.

18 January 2023 in Medical Sciences Forum
Verified
Conference Paper
Open access
PDF file
SBSabine Bou-Antoun
Sabine Bou-Antoun
AFAngela Falola
Angela Falola
HFHolly Fountain
Holly Fountain
HSHanna Squire
Hanna Squire
CBColin S. Brown
Colin S. Brown
ADAlicia Demirjian
Alicia Demirjian
The UK’s 5-year National Action Plan for Antimicrobial Resistance has an ambition to reduce total antimicrobial consumption, a key driver of antimicrobial resistance, in humans by 15% by 2024, highlighting the need for active surveillance to inform on progression. The English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) report, Chapter 3, commentates on key national antimicrobial consumption trends, across primary and secondary care in England, between 2017 to 2021. These findings were presented at the ESPAUR Report webinar on 23 November 2022.